Immunologic response and safety in birch pollen sublingual versus oral vestibule immunotherapy: A pilot study

Journal of Allergy and Clinical Immunology

Volumn 133, Issue 6, 2014, Pages

  Allam, Jean Pierre ^a   Wuestenberg, Eike ^b,c   Wolf, Hendrik ^c   Klimek, Ludger ^d   Decot, Elke ^e   Horn, Andreas ^f   Schnitker, Jörg ^g   Bieber, Thomas ^a   Novak, Natalija ^a  

^a UNIVERSITY OF BONN   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c ALK Abelló   (Germany)

^d Center for Rhinology and Allergy   (Germany)

^e Private Practice for Rhinology   (Germany)

^f Private Practice for Rhinology   (Germany)

^g Institut für Angewandte Statistik GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G4; POLLEN EXTRACT; SLITONE; UNCLASSIFIED DRUG; BIRCH POLLEN EXTRACT;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; APPLICATION SITE REACTION; BIRCH; CONTROLLED STUDY; DENDRITIC CELL; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; LETTER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL IMMUNOTHERAPY; PHASE 2 CLINICAL TRIAL; PILOT STUDY; POLLEN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT ALLERGY; SUBLINGUAL IMMUNOTHERAPY; TREATMENT OUTCOME; BETULA VERRUCOSA; GERMANY; GINGIVA; LIP; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOCONJUNCTIVITIS; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADMINISTRATION, SUBLINGUAL; ALLERGENS; BETULA; DESENSITIZATION, IMMUNOLOGIC; HUMANS; PILOT PROJECTS; POLLEN; RHINITIS, ALLERGIC, SEASONAL;

EID: 84901786828     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2014.03.026     Document Type: Article

References (9)

1. D.R. Wilson, M.T. Lima, and S.R. Durham Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis Allergy 60 2005 4 12
2. J.P. Allam, and N. Novak Local immunological mechanisms of sublingual immunotherapy Curr Opin Allergy Clin Immunol 11 2011 571 578
3. 4 correlate closely with clinical response to grass pollen immunotherapy Allergy 67 2012 217 226
4. J.P. Allam, P.A. Würtzen, M. Reinartz, J. Winter, S. Vrtala, and K.W. Chen et al. Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta 1 and IL-10-producing properties J Allergy Clin Immunol 126 2010 638 645.e1
5. + T cells J Allergy Clin Immunol 122 2008 603 609.e5
6. J.P. Allam, G. Stojanovski, N. Friedrichs, W. Peng, T. Bieber, and J. Wenzel et al. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? Allergy 63 2008 720 727 (Pubitemid 351591847)
7. S.R. Durham, W. Emminger, A. Kapp, J.G. de Monchy, S. Rak, and G.H. Scadding et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial J Allergy Clin Immunol 129 2012 717 725.e5
8. S. Senel, M. Kremer, K. Nagy, and C. Squier Delivery of bioactive peptides and proteins across oral (buccal) mucosa Curr Pharm Biotechnol 2 2001 175 186 (Pubitemid 32475723)
9. O. Amano, K. Mizobe, Y. Bando, and K. Sakiyama Anatomy and histology of rodent and human major salivary glands: overview of the Japan Salivary Gland Society-sponsored workshop Acta Histochem Cytochem 45 2012 241 250